Abstract
The antisense oligonucleotide company Ionis Pharmaceuticals will buy the 24% of Akcea Therapeutics stock that it does not already own for about $500 million. Ionis founded Akcea as a subsidiary to develop and commercialize experimental drugs Ionis designed. Akcea’s years of independence were marked by the US Food and Drug Administration’s rejection of its lead drug candidate, Waylivra, and competition for its second drug, Tegsedi. The firm has four drug candidates in Phase II and III trials.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
